Price
$184.56+17.91%Social Signal Score
Analyst Ratings
12 analystsRevenue
$551.68M+468.11%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Vivek Jain
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Employees
- 13,000
- Beta
- 0.76
- Country
- US
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 2.35
Financials
Revenue
$551.68M+468.1%Net Income
$19.09M+1.5%EBITDA
$141.34M+371.7%Free Cash Flow
$61.64M+198.1%EPS (diluted)
$0.76-30.3%Shares Outstanding (diluted)
25.04M+44.9%Operating Expenses
$174.62MCash & Debt
$298.30MReturn of Capital
$38.78MRevenue by Segment (annual)
$105.32MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $2.23B | $732.0K | $0.03 |
| 2024 | $2.38B | $-117.69M | $-4.83 |
| 2023 | $2.26B | $-29.66M | $-1.23 |
| 2022 | $2.28B | $-74.29M | $-3.11 |
| 2021 | $1.32B | $103.14M | $4.86 |
| 2020 | $1.27B | $86.87M | $4.16 |
| 2019 | $1.27B | $101.03M | $4.90 |
| 2018 | $1.40B | $28.79M | $1.33 |
| 2017 | $1.29B | $68.64M | $3.50 |
| 2016 | $379.37M | $63.08M | $3.90 |
| 2015 | $341.67M | $44.98M | $2.84 |
| 2014 | $309.26M | $26.34M | $1.72 |
| 2013 | $313.72M | $40.42M | $2.75 |
| 2012 | $316.87M | $41.28M | $2.90 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from ICUI's reported EPS growth of -29.7% a year over 13 years. Historical EPS growth of -30% would project the company towards zero. Floored at -15% as a starting point.
- EPS in 5 years
- $0.01
- Implied price
- $0.24
- Return from $159.38
- -72.8% a year
To earn 15.0% a year on these assumptions you'd need to buy at $0.12 — -99.9% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 12 | 15 | 18 | 21 | 24 |
|---|---|---|---|---|---|
| -25.0% | -77.9% | -76.9% | -76.0% | -75.2% | -74.6% |
| -20.0% | -76.4% | -75.3% | -74.4% | -73.6% | -72.9% |
| -15.0% | -74.9% | -73.8% | -72.8% | -71.9% | -71.2% |
| -10.0% | -73.4% | -72.2% | -71.2% | -70.3% | -69.5% |
| -5.0% | -72.0% | -70.7% | -69.6% | -68.6% | -67.8% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
100+56.05%Social Signal Score
Mentions (4)
- Newsgurufocus.com·13d ago·Neutral
A Look at ICU Medical Inc (ICUI) After 3.7% Gain -- GF Value $121.40 vs Price $160.98 On September 22, 2026, ICU Medical Inc (ICUI) shares rose 3.7%, bringing the current price to $160.98. The stock has fluctuated within a 52-week range of $112.5
View source ↗ - Newsfool.com·19d ago·Negative
ICU Medical CFO Brian Bonnell Sells 9,307 Shares Bonnell retains 62,443 direct shares.
View source ↗ - Newsseekingalpha.com·20d ago·Positive
ICU Medical, Inc. (ICUI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript ICU Medical, Inc. (ICUI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - News (Marketaux)insidermonkey.com·58d ago·Negative
Q2 Earnings Blowouts: 37 Stock That Beat Expectations ICU Medical, Inc</[+368 characters]
View source ↗
Earnings
Thu, Nov 5(in 4 weeks)
Consensus estimate $2.14 per share
Typical surprise +39.8% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$2.37 vs $1.91beat
- Thu, May 7$1.97 vs $1.78beat
- Thu, Feb 19$1.91 vs $1.68beat
- Thu, Nov 6$2.03 vs $1.43beat
- Thu, Aug 7$2.10 vs $1.44beat
- Thu, May 8$1.72 vs $1.23beat
Estimates and results for ICUI via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ICUI officers and directors.
- Bought
- —
- Sold
- $7.5m
0 trades
16 trades
- Sanzone Virginia Ruthsold
- Sanzone Virginia Ruthsold
- Sanzone Virginia Ruthsold
- Sanzone Virginia Ruthsold
- Bonnell Brian Michaelsold
- Bonnell Brian Michaelsold
- Bonnell Brian Michaelsold
- Bonnell Brian Michaelsold
84 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Gilbert Ray Cisneroshouse · CA31 · disclosed Jun 9, 2025 (34d later)Sell$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Nov 6, 2024 (6d later)Sell$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Mar 18, 2022 (32d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Jan 11, 2021 (19d later)Sell$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Jan 7, 2021 (17d later)Sell$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Oct 14, 2020 (19d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Oct 14, 2020 (21d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Oct 14, 2020 (20d later)Buy$15,001 - $50,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Apr 16, 2020 (16d later)Buy$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Sep 16, 2019 (52d later)Sell$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA39 · disclosed Sep 11, 2019 (27d later)Sell$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA39 · disclosed Aug 19, 2019 (20d later)Sell$1,001 - $15,000
- Thomas Roland Tillissenate · NC · disclosed Feb 26, 2015 (13d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.